Publication details

Léčba erlotinibem nemocných s nemalobuněčným karcinomem plic - efekt snížené dávky při závažných nežádoucích účincích.

Title in English Erlotinib treatment in patient with non-small cell lung cancer (NSCLC): The Effect of lowered dose in serious adverse events
Authors

PEŠEK M. KREJČÍ J. SKŘIČKOVÁ Jana

Year of publication 2010
Type Article in Proceedings
Conference XXXIV. Brněnské onkologické dny sborník
MU Faculty or unit

Faculty of Medicine

Citation
Field Pneumology
Keywords Erlotinib; NSCLC; serious adverse events; lowered dose
Description The authors discuss Erlotinib treatment in patient with non-small cell lung cancer (NSCLC)and the effect of lowered dose in case of serious adverse events.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info